IN2012MN02923A - - Google Patents

Info

Publication number
IN2012MN02923A
IN2012MN02923A IN2923MUN2012A IN2012MN02923A IN 2012MN02923 A IN2012MN02923 A IN 2012MN02923A IN 2923MUN2012 A IN2923MUN2012 A IN 2923MUN2012A IN 2012MN02923 A IN2012MN02923 A IN 2012MN02923A
Authority
IN
India
Prior art keywords
dosage forms
present
gaba
gastroretentive dosage
swelling
Prior art date
Application number
Other languages
English (en)
Inventor
Pratibha Sudhir Pilgaonkar
Maharukh Tehmasp Rustomjee
Anilkumar Surendrakumar Gandhi
Original Assignee
Rubicon Res Private Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Rubicon Res Private Ltd filed Critical Rubicon Res Private Ltd
Priority to IN2923MUN2012 priority Critical patent/IN2012MN02923A/en
Publication of IN2012MN02923A publication Critical patent/IN2012MN02923A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0065—Forms with gastric retention, e.g. floating on gastric juice, adhering to gastric mucosa, expanding to prevent passage through the pylorus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
IN2923MUN2012 2010-06-01 2011-06-01 IN2012MN02923A (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
IN2923MUN2012 IN2012MN02923A (fr) 2010-06-01 2011-06-01

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
IN1676MU2010 2010-06-01
IN2923MUN2012 IN2012MN02923A (fr) 2010-06-01 2011-06-01
PCT/IB2011/001200 WO2011151708A1 (fr) 2010-06-01 2011-06-01 Formes posologiques à rétention gastrique d'analogues de gaba

Publications (1)

Publication Number Publication Date
IN2012MN02923A true IN2012MN02923A (fr) 2015-06-05

Family

ID=54199435

Family Applications (1)

Application Number Title Priority Date Filing Date
IN2923MUN2012 IN2012MN02923A (fr) 2010-06-01 2011-06-01

Country Status (4)

Country Link
US (1) US20130078290A1 (fr)
EP (1) EP2575798B1 (fr)
IN (1) IN2012MN02923A (fr)
WO (1) WO2011151708A1 (fr)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2809303A1 (fr) 2012-01-30 2014-12-10 Ranbaxy Laboratories Limited Comprimés de prégabaline gastro-résistants
CA2863376A1 (fr) 2012-01-30 2013-08-08 Ranbaxy Laboratories Limited Comprimes gastro-resistants
EP2698144A1 (fr) * 2012-08-12 2014-02-19 Ali Raif Ilaç Sanayi ve Ticaret Anonim Sirketi Formulation de comprimé à libération prolongée contenant de la gabapentine dont l'aptitude à rester dans l'estomac est améliorée
IN2015DN04161A (fr) 2012-10-16 2015-10-16 Ranbaxy Lab Ltd
FR3014692B1 (fr) * 2013-12-18 2016-01-29 Ethypharm Sa Compositions pharmaceutiques orales a retention gastrique.
EP3099288A1 (fr) * 2014-01-28 2016-12-07 Sun Pharmaceutical Industries Ltd Comprimés à rétention gastrique stabilisée de prégabaline
KR102221846B1 (ko) * 2014-04-07 2021-02-26 영진약품 주식회사 안정성이 개선된 프레가발린을 함유하는 약제학적 조성물 및 이의 제조방법
WO2015174684A1 (fr) * 2014-05-14 2015-11-19 동아에스티 주식회사 Préparation à libération prolongée de rétention gastrique à libération contrôlée
WO2017058869A1 (fr) 2015-09-29 2017-04-06 Acorda Therapeutics, Inc. Compositions à libération prolongée de 4-aminopyridine
EP3426230B1 (fr) * 2016-03-10 2024-08-07 Orphelia Pharma Formes galéniques solides de vigabatrine
WO2018001582A1 (fr) * 2016-06-30 2018-01-04 Interquim, S.A. Comprimés multiples à base de ranolazine
KR102039345B1 (ko) 2017-02-01 2019-11-01 지엘팜텍주식회사 프레가발린 함유 고팽윤성 서방성 삼중정제
KR102039344B1 (ko) * 2017-02-01 2019-11-01 지엘팜텍주식회사 프레가발린 함유 경구용 서방성 삼중정제
KR102083241B1 (ko) * 2018-02-14 2020-03-02 환인제약 주식회사 라코사미드를 함유하는 약제학적 서방성 조성물
US11938222B2 (en) * 2018-06-13 2024-03-26 Beijing Tide Pharmaceutical Co., Ltd. Pregabalin sustained release composition and method for preparing the same
US11147767B2 (en) * 2019-02-25 2021-10-19 Rubicon Research Private Limited Gastroretentive formulations
EP3760190B1 (fr) * 2019-07-03 2023-05-24 Alvogen, Inc. Comprimés de prégabaline à libération contrôlée, son procédé de fabrication et son procédé d'utilisation
CN112741827B (zh) * 2019-10-31 2022-07-08 武汉武药科技有限公司 氨己烯酸固体制剂及其制备方法
EP4362919A1 (fr) * 2021-07-30 2024-05-08 Evecxia Therapeutics, Inc. Formes posologiques à rétention gastrique de 5-hydroxytryptophane
EP4392031A1 (fr) 2021-10-14 2024-07-03 Evecxia Therapeutics, Inc. Méthode d'optimisation de la fonction de la 5-hydroxytryptamine dans le cerveau à des fins thérapeutiques
CN114796142A (zh) * 2022-04-08 2022-07-29 黄山学院 萘普生胃漂浮片及其制备方法
WO2024148354A1 (fr) * 2023-01-06 2024-07-11 Evecxia Therapeutics, Inc. Méthode d'amélioration de l'exposition au 5-hydroxytryptophane (5-htp)

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4087544A (en) 1974-12-21 1978-05-02 Warner-Lambert Company Treatment of cranial dysfunctions using novel cyclic amino acids
DE2460891C2 (de) 1974-12-21 1982-09-23 Gödecke AG, 1000 Berlin 1-Aminomethyl-1-cycloalkanessigsäuren und deren Ester, Verfahren zu deren Herstellung und diese Verbindungen enthaltende Arzneimittel
US5084479A (en) 1990-01-02 1992-01-28 Warner-Lambert Company Novel methods for treating neurodegenerative diseases
US5025035A (en) 1990-10-12 1991-06-18 Warner-Lambert Company Method of treating depression
US6197819B1 (en) 1990-11-27 2001-03-06 Northwestern University Gamma amino butyric acid analogs and optical isomers
US5232704A (en) * 1990-12-19 1993-08-03 G. D. Searle & Co. Sustained release, bilayer buoyant dosage form
US5510381A (en) 1995-05-15 1996-04-23 Warner-Lambert Company Method of treatment of mania and bipolar disorder
BR9710536A (pt) 1996-07-24 1999-08-17 Warner Lambert Co Isobutilgaba e seus derivados para o tratamento da dor
HRP980342A2 (en) 1997-06-25 1999-02-28 Warner Lambert Co Anti-inflammatory method
ES2234139T3 (es) * 1997-08-11 2005-06-16 Alza Corporation Forma de dosificacion de un agente activo de liberacion prolongada adaptada para la retencion gastrica.
US6127418A (en) 1997-08-20 2000-10-03 Warner-Lambert Company GABA analogs to prevent and treat gastrointestinal damage
KR20040018394A (ko) 2001-07-04 2004-03-03 썬 파마슈티컬 인더스트리스 리미티드 위 정체 제어되는 약물 전달 계
TWI312285B (en) * 2001-10-25 2009-07-21 Depomed Inc Methods of treatment using a gastric retained gabapentin dosage
US6723340B2 (en) 2001-10-25 2004-04-20 Depomed, Inc. Optimal polymer mixtures for gastric retentive tablets
CN1668284A (zh) * 2002-06-07 2005-09-14 兰贝克赛实验室有限公司 加巴喷丁的缓释口服剂型
NL2000281C2 (nl) * 2005-11-02 2007-08-07 Pfizer Prod Inc Vaste farmaceutische samenstellingen die pregabaline bevatten.
AU2006332690A1 (en) * 2005-12-29 2007-07-12 Depomed, Inc. Gastric retentive gabapentin dosage forms and methods for using same
WO2009084040A1 (fr) * 2007-12-28 2009-07-09 Rubicon Research Private Limited Formule d'antagonistes des récepteurs de l'angiotensine administrée une fois par jour
ES2562925T3 (es) * 2008-12-04 2016-03-09 Intec Pharma Ltd. Sistema de administración de fármaco gastrorretentivo de zaleplón
WO2010143052A1 (fr) 2009-06-12 2010-12-16 Micro Labs Limited Nouvelles compositions pharmaceutiques contenant de la prégabaline
KR101317592B1 (ko) 2009-10-28 2013-10-15 씨제이제일제당 (주) 프레가발린, 폴리에틸렌옥사이드 및 폴리비닐알코올-폴리에틸렌글리콜 그라프트 공중합체를 함유하는 위체류형 서방성 제제

Also Published As

Publication number Publication date
EP2575798B1 (fr) 2017-08-09
US20130078290A1 (en) 2013-03-28
WO2011151708A1 (fr) 2011-12-08
EP2575798A1 (fr) 2013-04-10

Similar Documents

Publication Publication Date Title
IN2012MN02923A (fr)
PH12015501964A1 (en) Substituted 2-aza-bicyclo[2.2.1]heptane-3-carboxylic acid (benzyl-cyano-methyl)-amides inhibitors of cathepsin c
MY183588A (en) New salvianolic acid compound l, preparation method and use thereof
PH12015501385A1 (en) Autotaxin inhibitors
MX2015003653A (es) Derivados de amida del acido benzoimidazol-carboxilico como moduladores del receptor apj.
MX2012012225A (es) Profármacos de agentes tearapéuticos de liberación de óxido nítrico.
MX2015007900A (es) Esteroides neuroactivos sustituidos con 19-alcoxi-17, profarmacos de los mismos, y metodos de tratamiento usando los mismos.
MX2010002210A (es) Derivados de catecolamina y profarmacos de los mismos.
MX2013001677A (es) Formulaciones estables de linaclotida.
TN2011000370A1 (en) Alkylamine-substituted dicyanopyridine and amino acid ester prodrugs thereof
MX2019012939A (es) Formulaciones que contienen linaclotida para administracion oral.
MY156288A (en) Pharmaceutical formulations containing dopamine receptor ligands.
MY157673A (en) Pharmaceutical compositions comprising hydromorphone and naloxone
MX340983B (es) Composiciones farmaceuticas y nutraceuticas de acido abscisico.
MX344846B (es) Combinacion de granulos cargados activos con activos adicionales.
PH12015500823A1 (en) Modified release formulations for oprozomib
MX340188B (es) Elaboracion de granulos sin activos y tabletas que comprenden los mismos.
MX2012008413A (es) Composicion novedosa de retigabina.
TR201901792T4 (tr) Yeni (trimetoksifenilamino)pirimidinil formülasyonları.
UY33723A (es) ?COMPUESTOS Y SU USO PARA TRATAMIENTO DE ENFERMEDADES RELACIONADAS CON Aß?.
TR200909785A1 (tr) Aktif ajan olarak sefdinir içeren farmasötik kompozisyonlar.
MX2012015102A (es) Agentes terapeuticos 976.
UY32894A (es) Derivados de 5-fenil-pirazolopiridina, su preparación y su aplicación en terapéutica
PH12015502560B1 (en) Use of a thiazolo pyrimidinone for the treatment of inflammatory bowel disease
UA93515C2 (ru) Медикаментозное средство ha ochobe рутина